Voluntis (Euronext Growth Paris, Ticker: ALVTX – ISIN: FR0004183960), a leader in the field of digital therapeutics, announces that the company is going to meet French and European institutional investors with the brokerage firm Gilbert Dupont.
On this occasion, the company will review its positioning and development perspectives in the vast market of digital therapeutics, based on its rich portfolio of solutions co-developed with leading pharmaceutical companies.
The presentation, available on the company’s website via the link: https://www.www.voluntis.com/en/investors#documents , includes further details on the progress of the commercial pipeline of partnered DTx solutions, the global footprint of the company’s activities and the use of sales invoicing as an alternative performance indicator.
As a reminder, the brokerage firm Gilbert Dupont initiated Voluntis’ stock coverage last week with a study entitled “Algorithms enabling better care” and a €8.9 target price.
Next meeting: publication of the 2020 annual results on March 30, 2021, after the close of trading.
Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions, combining mobile and web apps, use clinical algorithms to deliver personalized recommendations to patients and their care teams. For example, these recommendations are used to adjust treatment dosage, manage side effects or monitor symptoms. Leveraging its Theraxium technology platform, Voluntis has designed and operates multiple digital therapeutics, especially in oncology and diabetes. Voluntis has long-standing partnerships with leading life science companies. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.